What is the Difference Between AML and ALL?

🆚 Go to Comparative Table 🆚

Acute myeloid leukemia (AML) and acute lymphocytic leukemia (ALL) are both cancers of the blood and bone marrow that affect the production of blood cells. The main difference between the two lies in the type of blood cells they affect. AML affects the production of myeloblasts, red blood cells, and platelets, while ALL mainly affects the production of lymphocytes, which are a type of white blood cell.

Here are some key differences between AML and ALL:

  • Affected Blood Cells: AML arises from myeloid precursor cells and affects the production of myeloblasts, red blood cells, and platelets. ALL, on the other hand, originates in lymphocytes, affecting the production of T cells, B cells, and NK cells.
  • Age Groups: ALL is more likely to affect children, with about 60% of cases occurring in children, particularly those under the age of 5. AML usually affects older adults.
  • Symptoms: Both AML and ALL share similar symptoms, such as weakness, loss of appetite, weight loss, fatigue, dizziness, and frequent infections. However, some symptoms are more specific to each type of leukemia.
  • Diagnosis: AML is diagnosed when there are leukemic blast cells present within the bone marrow at a certain percentage. ALL is diagnosed when there are leukemic blast cells related to the lymphoid line of cells at a certain percentage.
  • Treatment: Typically, the first-line treatment for both AML and ALL is chemotherapy, aiming to put the disease into remission. Follow-up consolidation therapy can help destroy any remaining cancer cells and maintain remission.
  • Prognosis: AML tends to progress rapidly and can be fatal within weeks or months without appropriate treatment. The prognosis for both AML and ALL depends on factors such as the patient's age, overall health, and the specific molecular characteristics of the cancer.

Comparative Table: AML vs ALL

Here is a table comparing the differences between Acute Myeloid Leukemia (AML) and Acute Lymphoblastic Leukemia (ALL):

Feature AML ALL
Affected Cells Myeloblasts, red blood cells, and platelets Lymphocytes
Bone Marrow Overproduction of myeloblasts, red blood cells, and platelets Overproduction of lymphocytes
Symptoms Weakness, loss of appetite, weight loss, dizziness, fatigue, shortness of breath, pale skin, and frequent infections Weakness, loss of appetite, weight loss, dizziness, fatigue, shortness of breath, pale skin, and frequent infections
Diagnosis Bone marrow aspiration and biopsy, cytometry and cytogenetic tests Bone marrow aspiration and biopsy, immunophenotyping and cytogenetic tests
Treatment Chemotherapy, consolidation therapy, and potentially stem cell transplantation Chemotherapy, consolidation therapy, and potentially stem cell transplantation
Survival Rates Variable, depending on factors such as age, subtype, and response to treatment Variable, depending on factors such as age, subtype, and response to treatment

Both AML and ALL are acute types of leukemia, which are cancers of the blood that begin in the bone marrow. They have similar symptoms, such as weakness, loss of appetite, weight loss, dizziness, fatigue, shortness of breath, pale skin, and frequent infections. The first-line treatment for both AML and ALL is typically chemotherapy, aiming to put the disease into remission, followed by consolidation therapy to destroy any remaining cancer cells and maintain remission.